

BavenoVII



ADVANCED PROGRAMME

CONSENSUS WORKSHOP PERSONALIZED CARE IN PORTAL HYPERTENSION



October 27-30, 2021

PEDIATRIC RESEARCH WORKSHOP

**Primary Prophylaxis of Variceal Hemorrhage, Complexities in the Development
of Evidence-Based Approaches in Pediatrics**

October 31, 2021

www.baveno7.com

Baveno VII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



BAVENO COOPERATION STEERING COMMITTEE

HONORARY PRESIDENT

Roberto de Franchis, *Milan (Italy)*

CHAIR

Jaime Bosch, *Bern (Switzerland)*

VICE-CHAIR

Guadalupe Garcia-Tsao, *New Haven (USA)*

Juan G. Abraldes, *Edmonton (UK)*

Agustin Albillos, *Madrid (Spain)*

Annalisa Berzigotti, *Bern (Switzerland)*

Gennaro D'Amico, *Palermo (Italy)*

Andrea De Gottardi, *Lugano (Switzerland)*

Alessandra Dell'Era, *Milan (Italy)*

Juan Carlos Garcia-Pagàn, *Barcelona (Spain)*

Joan Genescà, *Barcelona (Spain)*

Aleksander Krag, *Odense (Denmark)*

Wim Laleman, *Leuven (Belgium)*

Vincenzo La Mura, *Milan (Italy)*

Dominique Thabut, *Paris (France)*

Jonel Trebicka, *Frankfurt (Germany)*

Emmanouil Tsochatzis, *London (UK)*

Dominique Valla, *Paris (France)*

Candid Villanueva, *Barcelona (Spain)*

SCIENTIFIC SECRETARIES

Thomas Reiberger

Medical University of Vienna

Department of Internal Medicine III

Div. of Gastroenterology & Hepatology

Vienna Hepatic Experimental Hemodynamic Lab

Cristina Ripoll

Friedrich-Schiller University Jena,

Division of Internal Medicine IV, Jena, Germany

Baveno VII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



SUPPORTED BY



European Association for the Study of the Liver



Fundación Española para el Estudio del Hígado



American Association for the Study of Liver Diseases



Asian Pacific Association for the Study of the Liver



Associazione Italiana per lo Studio del Fegato



Japanese Society of Hepatology

ENDORSED BY

Baveno VII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



FACULTY

Juan G. Abraldes - *Edmonton, Canada*
Agustin Albillos - *Madrid, Spain*
Anna Baiges - *Barcelona, Spain*
Jasmohan Bajaj - *Richmond, Usa*
Rafael Bañares - *Madrid, Spain*
Marta Barrufet - *Barcelona, Spain*
Annalisa Berzigotti - *Bern, Switzerland*
Jaime Bosch - *Bern, Switzerland*
Christophe Bureau - *Toulouse, France*
Vincenza Calvaruso - *Palermo, Italy*
Andrés Cárdenas - *Barcelona, Spain*
Gennaro D'Amico - *Palermo, Italy*
Roberto de Franchis - *Milan, Italy*
Andrea De Gottardi - *Lugano, Switzerland*
Alessandra Dell'Era - *Milan, Italy*
Angels Escorsell - *Barcelona, Spain*
Jonathan Fallowfield - *Edinburgh, United Kingdom*
Hector Ferral - *Evanston, Usa*
Sven Francque - *Antwerp, Belgium*
Ron Gaba - *Chicago, Usa*
Juan Carlos Garcia Pagàn - *Barcelona, Spain*
Guadalupe Garcia-Tsao - *New Haven, Usa*
Joan Genescà - *Barcelona, Spain*
Susana Gomes Rodrigues - *Bern, Switzerland*
Jordi Gracia - *Barcelona, Spain*
Guohong Han - *Xi'an, China*
Ziv J. Haskal - *Charlottesville, Usa*
Virginia Hernandez-Gea - *Barcelona, Spain*
Jidong Jia - *Beijing, China*
Jean Jacques Kiladjian - *Paris, France*
Aleksander Krag - *Odense, Denmark*
Vincenzo La Mura - *Milan, Italy*
Wim Laleman - *Leuven, Belgium*

Baveno VII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



FACULTY

Sabela Lens - *Barcelona, Spain*
Xuefeng Luo - *Chengdu, China*
Mattias Mandorfer - *Vienna, Austria*
Sarwa Darwish Murad - *Rotterdam, The Netherlands*
Valerie Paradis - *Clichy, France*
David Patch - *London, United Kingdom*
Salvatore Piano - *Padua, Italy*
Massimo Pinzani - *London, United Kingdom*
Aurelie Plessier - *Clichy, France*
Massimo Primignani - *Milan, Italy*
Bogdan Procopet - *Cluj-Napoca, Romania*
Pierre Emmanuel Rautou - *Paris, France*
Thomas Reiberger - *Vienna, Austria*
Cristina Ripoll - *Halle, Germany*
Marika Rudler - *Paris, France*
Shiv K. Sarin - *New Delhi, India*
Filippo Schepis - *Modena, Italy*
Marco Senzolo - *Padua, Italy*
Vijay Shah - *Rochester, Usa*
Akash Shukla - *Mumbai, India*
Puneeta Tandon - *Edmonton, Canada*
Luis Tellez - *Madrid, Spain*
Dominique Thabut - *Paris, France*
Maja Thiele - *Odense, Denmark*
Jonel Trebicka - *Frankfurt, Germany*
Dhiraj Tripathi - *Birmingham, United Kingdom*
Emmanouil A. Tsochatzis - *London, United Kingdom*
Laura Turco - *Bologna, Italy*
Fanny Turon - *Barcelona, Spain*
Dominique Valla - *Clichy, France*
Candid Villanueva - *Barcelona, Spain*
Ian Wanless - *Halifax, Canada*
Hitoshi Yoshiji - *Kashiara, Japan*

Baveno VII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



WELCOME ADDRESS

Baveno VII is a sequel of the Baveno I-VI Workshops, which were held every 5 years from 1990 to 2015. All the previous Workshops were successful, as proven by more than 4000 citations of the Workshop reports in the medical literature.

After Baveno VI, important advances have been made in understanding the pathophysiology of portal hypertension, as well as in developing new treatments and new strategies for the management of advanced cirrhosis and portal hypertension. For these reasons, we thought that the time had come to organize a seventh Baveno Workshop.

Baveno VII was planned for March 2020 and had to be cancelled a few weeks before the meeting was to be held. At that point in time, we had no sense how the pandemic would develop, and we first decided to postpone the meeting to October 2020. By the summer, the Executive Committee realized that this option was not realistic and had to postpone again to October 2021. Finally, due to the persisting uncertainties, the Executive Committee has recently decided to cancel the face-to-face meeting. Therefore, Baveno VII will be a complete virtual meeting to be held over 4 days (27th to 30th October). The meeting will be held over 4 to 4h30 per day, starting at 14h00 European time.

As for the previous editions, the aim of the Baveno VII Workshop is twofold: first, to review and put into perspective the changes in diagnostic and therapeutic strategies that have occurred in the past 5 years in the field of portal hypertension, Second, to continue the effort - which had begun in Baveno I more than thirty years ago - of producing updated definitions and guidelines aimed at improving the management of patients as well as the quality of our future studies. The Workshop will begin with a brief introduction, followed by three lectures, the first one on the new concept of risk stratification, the second one on clinical stages and ordinal outcomes in portal hypertension, and the third on lifestyle and genetic modifiers of progression of compensated advanced chronic liver disease.

Baveno VII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



WELCOME ADDRESS

The structure of the Workshop is similar to that of the previous ones - there will be 4 sessions: each divided into 2-3 parts. The first session will concern the evaluation and risk stratification of patients with cirrhosis, focusing on the HVPG as a gold standard and on non-invasive surrogates for the diagnosis of compensated advanced chronic liver disease, clinically significant portal hypertension and varices. The second session, dedicated to the new clinical scenarios will be divided into three parts. The first one will include four introductory lectures on progression and regression of cirrhosis; the second one will analyze the impact of etiological therapy for cirrhosis, and the third one will deal with the impact of non-etiological novel therapies in cirrhosis. The third session will deal with the different clinical settings and will also be divided into three parts: the first one will be devoted to the prevention of (first) decompensation, the second one to acute variceal hemorrhage, and the third one to the prevention of further decompensation. The fourth session will be devoted to vascular liver diseases in cirrhosis and will consist of two parts: the first one on diagnosis and staging, and the second one on treatment. According to the Baveno tradition, at the end of each session, updated consensus statements on the topic of the session will be presented and discussed by the Panels and the Audience.



Roberto de Franchis

On behalf of the Baveno Cooperation Steering Committee

Baveno VII

CONSENSUS WORKSHOP

PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



SCIENTIFIC PROGRAMME

All times are CET

WEDNESDAY OCTOBER 27 2021

14:00-14.30 TRIBUTE TO THE BAVENO LEGENDS

Tom Boyer
Andy Burroughs
Roberto Groszmann
Luigi Pagliaro

14:30-15:15 INTRODUCTORY LECTURES

Welcome and introduction
R. de Franchis (*Milan, Italy*)

LECTURE-1: New concept of risk stratification
J.G. Abraldes (*Edmonton, Canada*)

LECTURE-2: Clinical stages and ordinal outcomes in portal hypertension
G. D'Amico (*Palermo, Italy*)

LECTURE-3: Lifestyle and genetic modifiers of liver disease progression
A. Berzigotti (*Bern, Switzerland*)

15.15-15.30 *Break*



SCIENTIFIC PROGRAMME

WEDNESDAY OCTOBER 27 2021

15.30-18.30 **SESSION 1**

EVALUATION AND RISK STRATIFICATION

15.30-16.15 **PART 1:** HVPG as a gold standard

Chairpersons: J.C. Garcia-Pagà (Barcelona, Spain), Z. Haskal (Charlottesville, Usa)

Panelists: R. Gaba (Chicago, Usa), H. Ferral (Evanston, Usa), F. Schepis (Modena, Italy)

- Quality Metrics in HVPG and Porto-Systemic Pressure Gradient (PPG)
- Usefulness of HVPG in:
 - a. the diagnosis of CSPH in cirrhosis of different etiologies
 - b. assessing the response to vasoactive drugs for risk stratification of variceal (re-)bleeding
 - c. assessing the prognosis of patients with cirrhosis
 - d. clinical trials vs. proof-of-concept studies
- PPG in the setting of TIPS
- Consensus statements

16.15-16.30 *Break*

16.30-18.30 **PART 2:** Noninvasive tools for cACLD and portal hypertension

Chairpersons: A. Berzigotti (Bern, Switzerland), J. Genescà (Barcelona, Spain)

Panelists: J.G. Abraldes (Edmonton, Canada), J. Fallowfield (Edinburgh, United Kingdom), M. Thiele (Odense, Denmark)

- cACLD and CSPH
- Detection of varices with noninvasive tools and screening endoscopy
- Use of noninvasive tools for prognosis in cirrhosis
- Spleen stiffness
- Emerging non-invasive markers: imaging, blood, and liver clearance tests
- Proposed consensus statements

End of the Day



SCIENTIFIC PROGRAMME

THURSDAY OCTOBER 28 2021

14:00-14:30 Presentation of selected abstracts

14.30-17.30 SESSION 2

NEW SCENARIOS

14.30-15.15 **PART 1:** Progression and regression of cirrhosis

Chairpersons: W. Laleman (Leuven), D. Patch (London)

LECTURE-4: PELS in progression. Can they regress?

I. Wanless (Halifax)

LECTURE-5: Fibrogenesis and regression of fibrosis

M. Pinzani (London)

LECTURE-6: Angiogenesis and progression of ACLD

V. Shah (Rochester)

15.15-15.30 *Break*

LECTURE-7: Drugs to modify liver fibrosis progression and regression (preclinical and clinical studies)

J. Gracia (Barcelona)



SCIENTIFIC PROGRAMME

THURSDAY OCTOBER 28 2021

15.45-16.30 **PART 2:** Impact of etiological therapies in the course of cirrhosis

Chairpersons: M. Mandorfer (Vienna, Austria), E. Tsochatzis (London, United Kingdom)

Panelists: S. Francque (Antwerp, Belgium), J. Jia (Beijing, China),
S. Lens (Barcelona, Spain), H. Yoshiji (Kashihara, Japan)

- Impact of etiological therapies on disease progression vs. regression in
 - Alcohol-related liver disease
 - Non-alcoholic fatty liver disease
 - Hepatitis B
 - Hepatitis C
- Presentation of recommendations for the management of cirrhosis after control of the primary etiological factor

16.30-16.45 *Break*

16.45-17.30 **PART 3:** Impact of non-etiological therapies in the course of cirrhosis

Chairpersons: A. Albillos (Madrid, Spain), J. Trebicka (Frankfurt, Germany)

Panelists: J. Bajaj (Richmond, Usa), J. Gracia (Barcelona, Spain),
A. Krag (Odense, Denmark), W. Laleman (Leuven, Belgium), V. Shah (Rochester, Usa)

- Impact of drugs acting on the gut/microbiome
- Impact of statins and FXR/PPAR agonists in the treatment of patients with cirrhosis and portal hypertension
- Use of anticoagulants (LMWH, DOAC) and antiplatelet drugs (ASS) in the management of cirrhosis and portal hypertension
- Proposed consensus statements

17.30-17.45 *Break*



SCIENTIFIC PROGRAMME

THURSDAY OCTOBER 28 2021

17.45-19.00 SESSION 3

CLINICAL SETTINGS

17.45-19.00 **PART 1:** Preventing (first) decompensation. Review of current evidence

Chairpersons: J. Bosch (Bern, Switzerland), C. Ripoll (Halle, Germany)

Panelists: R. Bañares (Madrid, Spain), V. Calvaruso (Palermo, Italy),
A. Dell'Era (Milan, Italy), S. Gomes Rodrigues (Bern, Switzerland),
D. Tripathi (Birmingham, United Kingdom), C. Villanueva (Barcelona, Spain)

- Results of the questionnaire
- Definition of decompensation:
 - Systematic review of studies that evaluate the natural history of cirrhosis and their definition of decompensation
 - The role of jaundice, perihepatic ascites, MHE and bleeding due to portal hypertensive gastropathy in the definition of decompensation
 - Impact of the sole presence of infection and of sarcopenia (without other manifestations of decompensation) in the natural history of compensated cirrhosis
- Use of NSBB in prevention of (first) decompensation:
 - Specific evaluation of the effect of CSPH, reduction of HVPG and other predictive factors
 - Meta-analysis with individual patient data on the effects of Carvedilol in the prevention of first decompensation
- Proposed Consensus Statements: Prevention of first decompensation

End of the Day



SCIENTIFIC PROGRAMME

FRIDAY OCTOBER 29 2021

14:00-14:30 Presentation of selected abstracts

14:30-15:30 INDUSTRY SPONSORED SYMPOSIUM

15:30-18.00 SESSION 3

CLINICAL SETTINGS (CONTINUED)

15:30-16:30 PART 2: Acute variceal bleeding

Chairpersons: V. Hernández-Gea (Barcelona, Spain), D. Thabut (Paris, France)

Panelists: A. Cárdenas (Barcelona, Spain), A. Escorsell (Barcelona, Spain),
G. Han (Xi'an, China), X. Luo (Chengdu, China), D. Patch (London, United Kingdom),
B. Procopet (Cluj-Napoca, Romania), M. Rudler (Paris, France)

- Patient Risk stratification and prognostic factors
- Novelties in general management of Acute Variceal Bleeding (AVB)
- Endoscopic management: classic and new therapies
- Pre-emptive TIPS
- Management of refractory bleeding
- Proposed consensus statements

16.30-16.45 Break



SCIENTIFIC PROGRAMME

FRIDAY OCTOBER 29 2021

16.45-18.00 **PART 3:** Preventing further decompensation. Review of current evidence

Chairpersons: **G. Garcia-Tsao** (New Haven, Usa), **T Reiberger** (Vienna, Austria)

Panelists: **C. Bureau** (Toulouse, France), **G. D'Amico** (Palermo, Italy),

V. La Mura (Milan, Italy), **S. Piano** (Padua, Italy),

P. Tandon (Edmonton, Canada), **L. Turco** (Bologna, Italy)

- Clinical concept of further decompensation: Outcomes and risk stratification
 - Mortality per type of initial event (ascites, variceal hemorrhage)
 - Further decompensation per type of initial event (VH or/and ascites)
- Prevention of further decompensation
 - Prevention of rebleeding and other further decompensating events
 - Should NSBB be used in patients with ascites for the prevention of further decompensation?
 - Readdress use of NSBB in patients with refractory ascites
 - TIPS - redefining candidates
- Sarcopenia and frailty- Exploring its relationship with further decompensation
- Concept of cirrhosis re-compensation

End of the Day

Baveno VII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



SCIENTIFIC PROGRAMME

SATURDAY OCTOBER 30 2021

14:00-15:00 INDUSTRY SPONSORED SYMPOSIUM

SESSION 4

VASCULAR LIVER DISORDERS

15.00-16.15 PART 1. SPLANCHNIC VEIN THROMBOSIS

Chairpersons: S. Sarin (New Delhi, India), D. Valla (Clichy, France)

Panelists: A. Baiges (Barcelona, Spain), M. Barrufet (Barcelona, Spain), J.J. Kiladjian (Paris, France), A. Plessier (Clichy, France), M. Primignani (Milan, Italy), A. Shukla (Mumbai, India), F. Turon (Barcelona, Spain)

- Portal vein thrombosis. Anticoagulation vs Interventional radiology
- Staging of portal vein thrombosis. Recurrent thrombosis and prognostic factors for recurrence
- Myeloproliferative neoplasia and splanchnic vein thrombosis: Diagnosis and management

16.15-16.30 *Break*



SCIENTIFIC PROGRAMME

SATURDAY OCTOBER 30 2021

16.30-17.45 **PART 2. OTHER ISSUES IN VASCULAR LIVER DISORDERS**

Chairpersons: A. de Gottardi (Lugano, Switzerland), P.E. Rautou (Paris, France)

Panelists: S. Murad (Rotterdam, The Netherlands), V. Paradis (Clichy, France), M. Senzolo (Padua, Italy), L. Tellez (Madrid, Spain)

- Anticoagulation (including DOACS) in cirrhotic and non-cirrhotic patients
- Portosinusoidal vascular disease/Idiopathic portal hypertension/non-cirrhotic portal hypertension: refining diagnostic criteria including histological criteria
- Presentation of Consensus Statements (both part 1 and 2)

17.45-18.00 *Break*

18.00-18.30 **DIGITAL BAVENO VII MEETING WRAP UP**

R. de Franchis (Milan, Italy)

G. Garcia-Tsao (New Haven, Usa)

J. Bosch (Bern, Switzerland)

End of the Workshop



PEDIATRIC RESEARCH WORKSHOP

BAVENO VII PEDIATRIC RESEARCH WORKSHOP

SUNDAY OCTOBER 31, 2021

**Primary Prophylaxis of Variceal Hemorrhage,
Complexities in the Development
of Evidence-Based Approaches in Pediatrics**

15.00-17.05* Background and Rationale for Investigation

15.00 Introduction and goals

B. Shneider (*Houston*)

15.05 Morbidity and Mortality of First Variceal Hemorrhage

J.P. Molleston (*Indianapolis*)

15.25 Experiences in Endoscopic Primary Prophylaxis

M. Duché (*Paris*)

15.45 Rationale for Primary Prophylaxis in Adults

R. de Franchis (*Milan*)

16.05 Complexity of a Randomized Clinical Trial in Pediatrics

S. Ling (*Toronto*)

16.25 International Registries in Pediatric Liver Diseases - The PSC Experience

M. Deneau (*Salt Lake City*)

16.45 Open Discussion - Q&A^

17.05-17.20 Break

Baveno VII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



PEDIATRIC RESEARCH WORKSHOP

17.20-19.30 Research Plan Discussion

17.20 Introduction of a Pediatric Portal Hypertension Registry
B. Shneider (Houston)

17.30 Presentation of the First Variceal Hemorrhage Database
J. Pimenta (Belo Horizonte)

17.45 Presentation of the Primary Prophylaxis Database
T. Grammatikopoulos (London)

18.00 Primary and Pre-primary Prophylaxis of Variceal Hemorrhage with the MesoRex Bypass and a MesoRex Bypass Registry
R. Superina (Chicago)

18.15 Registry Discussion[^]

19.00 Concluding Remarks
J. Bosch[^] (Berne)

19.15 Plans Forward
B. Shneider [^] (Houston)

* times CET [^] all talks are pre-recorded with the exception of the ones marked by [^] which will be as a panel discussion with on-line questions via a chat-type function

FACULTY

Jaime Bosch - Bern, Switzerland

Roberto de Franchis - Milan, Italy

Mark Deneau - Salt Lake City, USA

Mathieu Duché - Paris, France

Tassos Grammatikopoulos - London, United Kingdom

Simon C. Ling - Toronto, Canada

Jean P. Molleston - Indianapolis, USA

Júlio R. Pimenta - Belo Horizonte, Brazil

Benjamin L. Shneider - Houston, USA

Riccardo Superina - Chicago, USA



INDUSTRY SPONSORED SYMPOSIUM

FRIDAY OCTOBER 29 2021

14:30-15:30 INDUSTRY SPONSORED SYMPOSIUM

20 Years of Experience with TIPS: Historical overview and future outlook

Chairman: T. Reiberger (Vienna, Austria)

LECTURE: The history of the TIPS procedure: indications, patients, and device evolution. Experience with the GORE VIATORR TIPS Endoprosthesis

J. Bosch (Bern, Switzerland)

LECTURE: The future of small diameter TIPS. What tools do we have to better predict outcomes and minimize post-TIPS complications

J. Trebicka (Frankfurt, Germany)

SATURDAY OCTOBER 30 2021

14:00-15:00 INDUSTRY SPONSORED SYMPOSIUM

EUS-guided portal pressure measurement: expanding the horizon in portal hypertension assessment

Baveno VII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



REGISTRATION FEE

(22% VAT included- VAT is quoted according to the actual rate in force. All rates will be updated in case of legal changes in the applicable rates)

• EARLY BIRD REGISTRATION - till September 10, 2021	€ 450,00
• FULL REGISTRATION - after September 10, 2021	€ 550,00
• PEDIATRIC RESEARCH WORKSHOP**	€ 75,00
• YOUNG INVESTIGATOR EARLY BIRD FEE* - till September 10, 2021	€ 150,00
• YOUNG INVESTIGATOR FULL REGISTRATION - after September 10, 2021	€ 200,00
• YOUNG INVESTIGATOR PEDIATRIC RESEARCH WORKSHOP**	€ 25,00

* Young investigators must be under 35 years old and still in training at the time of the Workshop. Proof of age and training status is mandatory

** Registration in the Baveno VII Workshop is mandatory to register for the Pediatric Research Workshop

The Registration fee includes:

- Admission to scientific sessions
- Admission to the exhibition area
- Attendance Certificate

HOW TO REGISTER IN THE WORKSHOP

Registration can be made online through the www.baveno7.com website and paid by credit card. Registration for the Workshop must be forwarded within October 1, 2021.